Literature DB >> 19701106

Prognostic value of 18F-FDG uptake on positron emission tomography in patients with pathologic stage I non-small cell lung cancer.

Sang-Won Um1, Hojoong Kim, Won-Jung Koh, Gee Young Suh, Man Pyo Chung, O Jung Kwon, Joon Young Choi, Joungho Han, Kyung Soo Lee, Jhingook Kim.   

Abstract

INTRODUCTION: The intensity of 18F-fluorodeoxyglucose (18F-FDG) uptake in positron emission tomography could be of prognostic significance for patients with non-small cell lung cancer (NSCLC). The aim of this retrospective study was to evaluate the prognostic value of the FDG uptake in patients with resected pathologic stage I NSCLC according to histologic types of the tumors.
METHODS: For each patient, a maximum standardized uptake value (SUVmax) and a partial volume corrected (PVC) SUVmax were calculated for the primary lesion on positron emission tomography. To find optimal cutoff values for cancer recurrences, receiver operating characteristic curves were used.
RESULTS: Among 145 study patients, the mean values of SUVmax were 7.7 in those with adenocarcinoma (n = 70) and 16.0 in those with other histologies (n = 75; p < 0.001). Furthermore, the optimal cutoff values of SUVmax to predict cancer recurrences were identified as 5.2 in patients with adenocarcinoma and 13.8 in those with other histologies. In whole patients with pathologic stage I NSCLC, SUVmax (p = 0.025), PVC SUVmax (p = 0.014), tumor size (p = 0.048), and weight loss (p = 0.041) were significantly associated with disease-free survival (DFS). Moreover, PVC SUVmax (p = 0.034) and SUVmax (p = 0.012) were significantly associated with DFS in the multivariate analyses.
CONCLUSIONS: The intensity of FDG uptake for the primary tumor was an independent prognostic factor for DFS in whole patients with pathologic stage I NSCLC. However, caution is needed for the interpretation of optimal cutoff values of SUVmax according to tumor histologies.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19701106     DOI: 10.1097/JTO.0b013e3181b6be3e

Source DB:  PubMed          Journal:  J Thorac Oncol        ISSN: 1556-0864            Impact factor:   15.609


  13 in total

1.  Independent prognostic value of whole-body metabolic tumor burden from FDG-PET in non-small cell lung cancer.

Authors:  Hao Zhang; Kristen Wroblewski; Daniel Appelbaum; Yonglin Pu
Journal:  Int J Comput Assist Radiol Surg       Date:  2012-05-30       Impact factor: 2.924

Review 2.  Pulmonary subsolid nodules: what radiologists need to know about the imaging features and management strategy.

Authors:  Hyungjin Kim; Chang Min Park; Jae Moon Koh; Sang Min Lee; Jin Mo Goo
Journal:  Diagn Interv Radiol       Date:  2014 Jan-Feb       Impact factor: 2.630

Review 3.  Prognostic value of metabolic tumor burden in lung cancer.

Authors:  Piotr Obara; Yonglin Pu
Journal:  Chin J Cancer Res       Date:  2013-12       Impact factor: 5.087

4.  FDG-PET maximum standardized uptake value is prognostic for recurrence and survival after stereotactic body radiotherapy for non-small cell lung cancer.

Authors:  Zachary A Kohutek; Abraham J Wu; Zhigang Zhang; Amanda Foster; Shaun U Din; Ellen D Yorke; Robert Downey; Kenneth E Rosenzweig; Wolfgang A Weber; Andreas Rimner
Journal:  Lung Cancer       Date:  2015-05-28       Impact factor: 5.705

Review 5.  International association for the study of lung cancer/american thoracic society/european respiratory society international multidisciplinary classification of lung adenocarcinoma.

Authors:  William D Travis; Elisabeth Brambilla; Masayuki Noguchi; Andrew G Nicholson; Kim R Geisinger; Yasushi Yatabe; David G Beer; Charles A Powell; Gregory J Riely; Paul E Van Schil; Kavita Garg; John H M Austin; Hisao Asamura; Valerie W Rusch; Fred R Hirsch; Giorgio Scagliotti; Tetsuya Mitsudomi; Rudolf M Huber; Yuichi Ishikawa; James Jett; Montserrat Sanchez-Cespedes; Jean-Paul Sculier; Takashi Takahashi; Masahiro Tsuboi; Johan Vansteenkiste; Ignacio Wistuba; Pan-Chyr Yang; Denise Aberle; Christian Brambilla; Douglas Flieder; Wilbur Franklin; Adi Gazdar; Michael Gould; Philip Hasleton; Douglas Henderson; Bruce Johnson; David Johnson; Keith Kerr; Keiko Kuriyama; Jin Soo Lee; Vincent A Miller; Iver Petersen; Victor Roggli; Rafael Rosell; Nagahiro Saijo; Erik Thunnissen; Ming Tsao; David Yankelewitz
Journal:  J Thorac Oncol       Date:  2011-02       Impact factor: 15.609

Review 6.  KSNM60 in Clinical Nuclear Oncology.

Authors:  Seung Hwan Moon; Young Seok Cho; Joon Young Choi
Journal:  Nucl Med Mol Imaging       Date:  2021-08-31

7.  Metabolic burden measured by (18)f-fluorodeoxyglucose positron emission tomography/computed tomography is a prognostic factor in patients with small cell lung cancer.

Authors:  Mi-Hyun Kim; Ji Seok Lee; Jeong Ha Mok; Kwangha Lee; Ki Uk Kim; Hye-Kyung Park; Seong-Jang Kim; Min Ki Lee
Journal:  Cancer Res Treat       Date:  2014-04-22       Impact factor: 4.679

Review 8.  Prognostic Value of 18F-FDG PET/CT in Surgical Non-Small Cell Lung Cancer: A Meta-Analysis.

Authors:  Jing Liu; Min Dong; Xiaorong Sun; Wenwu Li; Ligang Xing; Jinming Yu
Journal:  PLoS One       Date:  2016-01-04       Impact factor: 3.240

9.  The maximum standardized FDG uptake on PET-CT in patients with non-small cell lung cancer.

Authors:  Mehmet Akif Ozgül; Gamze Kirkil; Ekrem Cengiz Seyhan; Erdoğan Cetinkaya; Güler Ozgül; Mahmut Yüksel
Journal:  Multidiscip Respir Med       Date:  2013-10-22

10.  Prognostic Value of Fluoro-D-glucose Uptake of Primary Tumor and Metastatic Lesions in Advanced Nonsmall Cell Lung Cancer.

Authors:  Xuan Canh Nguyen; Van Khoi Nguyen; Minh Thong Tran; Simone Maurea; Marco Salvatore
Journal:  World J Nucl Med       Date:  2014-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.